You need to be logged in to view this video

New Frontiers in Medicine - Novel Biopharmaceuticals to Potentially Reverse Neurodegenerative Diseases

Released on Friday, February 8, 2019•HEALTHCARE

Share
Facebook Twitter LinkedIn SMS

The presentation will introduce our hypotheses that most neurodegenerative diseases are caused by "vascular disorder" and that FGF-1 drug maybe able through angiogenesis and neurogenesis to regenerate the brain and cure these diseases. Scientific, medical and clinical data will be presented. Zhittya anticipates filling Investigative New Drug Applications with the FDA for (1) Parkinson's, (2) ALS, (3) Alzheimer's (4) stroke recovery and (5) Multiple sclerosis in the first half of 2019.
The presentation will introduce a revolutionary new treatment for these diseases.

Jack Jacobs

Zhittya Genesis Medicine, Inc., President and Chief Scientific Officer

Dr. Jack Jacobs has been involved in the healthcare industry for over 25 years and has extensive expertise in supervising drug manufacturing operations, as well as the design and implementation of preclinical animal trials and US FDA-authorized clinical trials. He started a new department of biological chemistry at Merck and for 15 years worked with Mr. Daniel Montano as cardiovascular biotherapeutics' chief scientific officer. Dr. Jacobs oversaw FDA-authorized clinical trials in which FGF-1 was tested in a number of medical indications, including coronary artery disease, diabetic foot ulcers, and peripheral artery disease. He also oversaw the manufacturing of clinical lots of FGF-1 that were used in those clinical studies. Dr. Jacobs received a BS degree from Davidson College and a PhD in molecular biology from Washington University, St. Louis.